Insider · CIK 0002042021
Amy Schacterle
officer
Files at ABOS (Acumen Pharmaceuticals, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 6, 2025 | ABOS Acumen Pharmaceuticals, Inc. | AGrant or award Common Stock | +8,800 | $0.00 | $0 | 8,800 | Jan 7, 2025 |
| Jan 6, 2025 | ABOS Acumen Pharmaceuticals, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +13,200 | $0.00 | $0 | 13,200 | Jan 7, 2025 |
| Nov 5, 2024 | ABOS Acumen Pharmaceuticals, Inc. | AGrant or award Employee Stock Option (right to buy)derivative | +340,000 | $0.00 | $0 | 340,000 | Nov 6, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.